Head and Neck Surgery, National Institute of Oncology Hungary, 1122, Budapest, Hungary.
Department of Medical Oncology, Shaqlawa Teaching Hospital, Shaqlawa, Erbil, 44005, Iraq.
Cancer Treat Res. 2023;188:353-368. doi: 10.1007/978-3-031-33602-7_14.
There is a growing global debate over barriers affecting the timely access to innovative anticancer therapies. Access to medicines is often traced back to the issue of costs: however, more commonly, the distance between valuable innovative treatments and the actual treatment of patients is far beyond the mere problem of financial barriers. A comprehensive approach to understand, assess to medicines should be pursued, to dissect the determinants and formulate solutions for all patients. In this chapter, we discuss drivers of access to innovation for patients with breast cancer, based on a case study of access to HER2-diagnositcs and therapeutics yielding a global landscape analysis, based on the efforts and expertise of the global collaborative group "ONCOLLEGE".
全球范围内对于影响及时获得创新抗癌疗法的障碍存在越来越多的争论。药物的可及性通常可以追溯到成本问题:然而,更常见的情况是,有价值的创新疗法与实际治疗患者之间的距离远远超出了单纯的财务障碍问题。应该采取综合方法来理解和评估药物,以剖析决定因素并为所有患者制定解决方案。在本章中,我们基于 HER2 诊断和治疗药物的可及性案例研究,探讨了乳腺癌患者获得创新药物的驱动因素,并基于全球协作组织“ONCOLLEGE”的努力和专业知识进行了全球景观分析。